A pharmaceutically acceptable salt or ester of a substituted 1h-tetrazolyl spiro[chroman-2,4'-piperidine]-1-one compound.

Abstract

The invention relates to a pharmaceutically acceptable salt or ester of a compound of a general formula (1): wherein Ar1 represents a group formed from an aromatic ring selected from a group consisting of indole, benzimidazole and 1,2-benzisoxazole, having R3 and R4 , and optionally having a substituent selected from a group consisting of a halogen atom, a hydroxyl group, a C1-C6 alkyl group, a halo-C1-C6 alkyl group, a hydroxy-C1-C6 alkyl group, a cyclo-C3-C6 alkyl group, a C1-C6 alkoxy group, a halo-C1-C6 alkoxy group and carbamoyl group; R1 represents a phenyl group optionally substituted with a carboxyl group, a tetrazolyl group optionally substituted with a C2-C7 alkanoyloxy-C1-C6 alkyl group, a pyridyl group optionally substituted with a C1-C6 alkyl group or a carboxyl group, a dihydro1,2,4-triazolyl group optionally substituted with an oxo group, or a dihydro-1,2,4oxadiazolyl group optionally substituted with an oxo group; R2 represents a hydrogen atom, a halogen atom, a C1-C6 alkyl group, or a C1-C6 alkoxy group; and R3 and R4 each independently represent a hydrogen atom, a halogen atom, nitro group, a cyclo¬C3-C6 alkyl group, a carbamoyl group optionally substituted with a C1-C6 alkyl or cyclo-C3-C6 alkyl group, a C1-C6 alkoxy group optionally substituted with a hydroxyl group, or a C1C6 alkyl group optionally substituted with a hydroxyl group, as therapeutical agent for various ACC-related diseases.